At Stanford Medicine and research centers across 19 countries, 194 patients with IgG4-related disease have just experienced what many never thought possible: a treatment that controls their condition without crippling their immune system. The results, published in the New England Journal of Medicine, show that a drug called obexelimab cuts the risk of disease relapse in half—a breakthrough that arrives after decades of misdiagnosis and limited options for a disorder that silently damages organs while masquerading as cancer.
IgG4-related disease is a rare chronic immune condition that affects an estimated 10,000 to 30,000 Americans, though physicians like Dr. Matthew Baker suspect the true number is far higher. The disease causes the body's own B cells to attack healthy tissue, triggering severe inflammation and fibrosis—a thickening of connective tissue that can create tumor-like masses throughout the body. Patients often spend years pursuing a correct diagnosis while their organs deteriorate. The soft tissue swelling in the pancreas, salivary glands, kidneys, and lymph nodes looks so much like cancer that many undergo invasive biopsies or surgery before clinicians finally recognize what they're actually dealing with. It has only been formally recognized as a distinct disease for about 25 years.
Until now, doctors have relied on drugs like rituximab and inebilizumab—medications that work by destroying B cells entirely. These therapies are effective, but they come with a serious cost: patients lose a critical part of their immune defense and become vulnerable to severe infections. The effects can linger for months even after stopping treatment, leaving patients in a precarious position.
Obexelimab takes a fundamentally different approach. Instead of eliminating B cells, it inhibits their function by binding to them and switching off their destructive activity. The drug was developed by Zenas BioPharma and represents a gentler way to treat immune diseases that involve misdirected B cells.
The international trial enrolled 194 patients at 114 sites across 19 countries. All participants first received steroids to achieve remission, then were randomly assigned to receive either weekly injections of obexelimab or placebo over 52 weeks while their steroid doses were gradually withdrawn. The results were striking: only 26.8% of patients on obexelimab experienced a relapse, compared with 54.6% in the placebo group. That 50% reduction in relapse risk represents the kind of progress that reshapes treatment options for rare diseases.
Dr. Matthew Baker, an associate professor of immunology and rheumatology at Stanford and co-first author of the study, captured the significance plainly: "Patients with IgG4-related disease can spend years pursuing a diagnosis while their organs are being damaged; even then, the treatment options have been limited. Having something that works this well, and may be safer than what is currently available, is a real step forward."
The research was led by a global team including Emanuel Della-Torre of Vita-Salute San Raffaele University, John Stone of Massachusetts General Brigham, and Emma Culver of University of Oxford. Their findings suggest that the future of treating B-cell-driven diseases may lie not in elimination, but in precision control—sparing patients the collateral damage while still conquering the disease.